Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function)

High retention rate with 90% of patients entering the OLE remaining in the study at one year

Canvuparatide was generally well tolerated with no new safety signals during the OLE

PK supports once-weekly dosing, with low peak-to-trough ratio and stable exposure

Phase 3 pivotal trial remains on track to initiate in Q3 2026

Company to host conference call today at 8:00 a.m. ET

CARMEL, Ind. and BURLINGTON, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced full results from the 12-week Avail™ Phase 2 trial and new one-year data from the ongoing open-label extension (OLE) study of once-weekly canvuparatide in adult patients with chronic hypoparathyroidism.